- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06196684
Early Safety and Clinical Efficacy of Mitral Allograft in Tricuspid Surgery (ESEMATS)
December 26, 2023 updated by: Mikhail Nuzhdin, Chelyabinsk Regional Clinical Hospital
Early Safety and Clinical Efficacy of Mitral Allografts in Patients With Primary Tricuspid Valve Disease Scheduled for Tricuspid Valve Replacement
The aim of the study is to evaluate early safety and clinical efficacy of mitral allografts in tricuspid valve replacement for primary tricuspid valve diseases.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
Early safety (morbidity, mortality rate, freedom from any valve related complication) along with mid-term clinical efficacy ( mid-term survival, freedom from reoperation, repeat endocarditis and other valve related complication ) is going to be evaluated.
Study Type
Observational
Enrollment (Estimated)
30
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Mikhail Nuzhdin
- Phone Number: +79068608612
- Email: austesla2022@gmail.com
Study Contact Backup
- Name: Yury Malinovsky
- Phone Number: +73517493732
- Email: adastramnd@mail.ru
Study Locations
-
-
-
Chelyabinsk, Russian Federation, 454076
- Recruiting
- Department of Cardiac Surgery
-
Contact:
- Yury Malinovsky, PhD
- Phone Number: +73517493732
- Email: evgenikud12@hotmail.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Probability Sample
Study Population
Patients with primary tricuspid valve disease
Description
Inclusion Criteria:
- Patients with primary tricuspid valve disease and/or tricuspid bioprosthetic failure scheduled for tricuspid valve intervention.
- Intraoperative findings suggested for tricuspid valve replacement rather than repair.
Exclusion Criteria:
- Pregnancy
- Confirmed active drug addiction
- Progressive HIV-infection
- HIV-infected patients with CD4-cells count less than 250
- Patients with secondary tricuspid valve pathology (left-sided valve disease)
- LV Ejection fraction less than 50%
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Patients with primary tricuspid valve insufficiency scheduled for tricuspid valve replacement
|
Tricuspid valve replacement with mitral valve allograft
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mortality (all cause and valve-related)
Time Frame: 30-day period
|
Estimate rate of mortality (all cause and valve-related)
|
30-day period
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Neurologic events
Time Frame: 30-day period
|
any neurological events in 30-day period
|
30-day period
|
Bleeding and transfusions
Time Frame: 30 days
|
Freedom from major bleeding events
|
30 days
|
Cardiac structural complications
Time Frame: 30 days
|
any structural cardiac complication
|
30 days
|
Acute kidney injury
Time Frame: 30 days
|
freedom from type 3-4 AKI
|
30 days
|
Allograft valve dysfunction
Time Frame: 30 days
|
freedom from allograft valve stenosis or regurgitation
|
30 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 29, 2021
Primary Completion (Estimated)
September 29, 2024
Study Completion (Estimated)
October 30, 2024
Study Registration Dates
First Submitted
December 26, 2023
First Submitted That Met QC Criteria
December 26, 2023
First Posted (Actual)
January 9, 2024
Study Record Updates
Last Update Posted (Actual)
January 9, 2024
Last Update Submitted That Met QC Criteria
December 26, 2023
Last Verified
December 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 26122023
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tricuspid Valve Insufficiency
-
Medical College of WisconsinChildren's Hospital and Health System Foundation, WisconsinCompletedMitral Valve Regurgitation | Tricuspid Valve Regurgitation, Non-rheumaticUnited States
-
Edwards LifesciencesActive, not recruitingTricuspid Regurgitation | Tricuspid InsufficiencyGermany, Spain, Switzerland
-
VDyne, Inc.RecruitingTricuspid Regurgitation | Tricuspid Valve Disease | Tricuspid Valvular DisordersAustralia, Czechia, Austria
-
Azienda Ospedaliero, Universitaria PisanaNot yet recruitingSevere Tricuspid Valve Regurgitation
-
CroiValve LimitedRecruitingHeart Valve Diseases | Tricuspid Valve Insufficiency | Tricuspid Regurgitation | Tricuspid Valve DiseaseUnited States
-
Baylor Research InstituteTerminatedTricuspid Regurgitation | Tricuspid Valve DiseaseUnited States
-
P+F Products + Features GmbHMeditrial USA Inc.Not yet recruitingTricuspid Regurgitation | Tricuspid Valve DiseaseUnited States
-
Michele De BonisCompleted
-
VDyne, Inc.Not yet recruitingTricuspid Regurgitation | Tricuspid Valve Disease | Tricuspid Valvular DisordersUnited States
-
P+F Products + Features GmbHRecruitingHeart Diseases | Heart Failure | Heart Valve Diseases | Tricuspid Valve Insufficiency | Tricuspid Regurgitation | Tricuspid InsufficiencySpain, Germany, Austria, Belgium, Lithuania
Clinical Trials on Mitral allograft implantation
-
Kantonsspital Winterthur KSWTerminatedErectile Dysfunction Following Radical ProstatectomySwitzerland
-
Wake Forest University Health SciencesSamaritan BiologicsWithdrawnProstate CancerUnited States
-
Abbott Medical DevicesRecruitingMitral Valve RegurgitationNorway, United Kingdom, Saudi Arabia, France, Germany, Italy, Austria, Belgium, Czechia, Israel, Netherlands, Spain, Switzerland
-
Medical University of WarsawInstitute of Cardiology, Warsaw, Poland; Medical University of Lodz; Medical... and other collaboratorsRecruitingHeart Failure | Mitral Insufficiency | Mitral Stenosis | Mitral Stenosis With Insufficiency | Bioprosthesis FailurePoland
-
Hospices Civils de LyonWithdrawn
-
Abbott Medical DevicesRecruiting
-
University of Alabama at BirminghamBioDlogicsActive, not recruiting
-
University of LouisvilleCompletedAlveolar Process DefectUnited States
-
The University of Texas Health Science Center at...CompletedDental Alveolus | Oral Surgical Procedures, PreprostheticUnited States